Feasibility of Saliva and Remote Monitoring of Active Cytomegalovirus (CMV) Infection and Symptoms During Ovarian Cancer Treatment

Mayo Clinic49 enrolled

Overview

This study evaluates the feasibility and accuracy of using saliva to remotely monitor cytomegalovirus (CMV) infection in individuals receiving treatment for ovarian cancer.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Interventions

Non-Interventional StudyOTHER

Non-Interventional Study

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥ 18 * Ability to read and write in English * Diagnosed with ovarian cancer (ovarian, primary peritoneal, fallopian tube) * Receiving care from providers at Mayo Clinic * Regardless of diseases status, actively receiving treatment for ovarian cancer (frontline, maintenance, progression, recurrence) Exclusion Criteria: * Pregnant at the time of study participation * Inability to provide informed written consent * History of dementia, stroke, brain tumors or other condition which may impair cognitive functioning

Locations (2)

University of Minnesota/Masonic Cancer Center

Minneapolis, Minnesota, United States

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Outcomes

Primary Outcomes

Using saliva and blood samples to remotely monitor cytomegalovirus (CMV) infection

Assessed through collection and comparison of blood and saliva samples collected from individuals receiving treatment for ovarian cancer. Samples may be collected in clinic or at home following study enrollment. Saliva will be self-collected using Oragene OGR-600 kits. Blood samples will be collected at the time of another scheduled clinic blood draw (Aim 1) or at home through a home phlebotomy service (Aim 2).

Time frame: Baseline

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.